At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 313 enrolled
Drug / intervention
Cinacalcet +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis
In Brief
A Phase 4 clinical trial evaluating Cinacalcet and Vitamin D for Chronic Kidney Disease and Secondary Hyperparathyroidism. Completed, enrolled 313 participants.
Detailed Summary
Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartFeb 2009
Primary CompletionDec 2010
Study CompletionJul 2011
TodayJul 2026
First PostedDec 5, 2008
Enrollment StartFeb 1, 2009
Primary CompletionDec 9, 2010
Study CompletionJul 5, 2011
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 17.6 years ago
Interventions
Cinacalcetdrug
Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
Vitamin Ddrug
Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.